| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 349.00 | 11.3% | 16.2% |
| Total Income | 349.00 | 11.1% | 15.6% |
| Expenditure | 359.68 | 11.0% | 22.5% |
| PBT | -17.43 | 72.6% | 315.4% |
| Net Profit | -17.43 | 72.6% | 315.4% |
| OPM | 8.77% | 2.31pp | 23.58pp |
| NPM | -4.99% | 1.77pp | 7.67pp |
| EPS | 3.98 | 68.6% | 96.1% |
Solara Active Pharma Sciences Announces Q3 and Nine Months Results for 2025, Expects to Raise Rs. 134.99 Crores
06 Feb 2026 · 6 Feb, 1:56 pm
Summary
Solara Active Pharma Sciences has announced its Q3 and nine months results for the year 2025. The company's Board of Directors approved the unaudited financial results, which were prepared in accordance with the Indian Accounting Standard 34 and other accounting principles generally accepted in India. The company's revenue from operations stands at Rs. 1,010.75 Crores for the quarter and Rs. 2,294.52 Crores for the nine months ended December 31, 2025.
Key Highlights
- 1
Revenue from operations for the quarter is Rs. 1,010.75 Crores
- 2
Revenue from operations for the nine months ended December 31, 2025, is Rs. 2,294.52 Crores
- 3
The company expects to raise Rs. 134.99 Crores
- 4
The results were approved by the Board of Directors in a meeting held on February 06, 2026
Informational and educational content only. Not investment advice.